Rankings
▼
Calendar
KNSA Q4 2019 Earnings — Kiniksa Pharmaceuticals, Ltd. Revenue & Financial Results | Market Cap Arena
KNSA
Kiniksa Pharmaceuticals, Ltd.
$3B
Q4 2019 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
$0
Operating Income
-$33M
Net Income
-$32M
EPS (Diluted)
$-0.58
QoQ Revenue Growth
NaN%
Cash Flow
Operating Cash Flow
-$24M
Free Cash Flow
-$26M
Stock-Based Comp.
$5M
Balance Sheet
Total Assets
$255M
Total Liabilities
$29M
Stockholders' Equity
$225M
Cash & Equivalents
$47M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$0
$0
—
Gross Profit
$0
$0
—
Operating Income
-$33M
-$44M
+26.2%
Net Income
-$32M
-$43M
+25.3%
← FY 2019
All Quarters
Q1 2020 →